This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2008 Sep;111(2):389-90.

doi: 10.1007/s10549-007-9777-3. Epub 2007 Oct 4.

Invasiveness gene signature predicts a favorable outcome also in estrogen receptor-positive primary breast cancers treated with adjuvant tamoxifen

Danila Coradini, Manuela Gariboldi, Maya Fedeli, Marco A Pierotti, Maria Grazia Daidone

PMID: 17914668
DOI: 10.1007/s10549-007-9777-3

Invasiveness gene signature predicts a favorable outcome also in estrogen receptor-positive primary breast cancers treated with adjuvant tamoxifen

Danila Coradini et al. Breast Cancer Res Treat. 2008 Sep.

. 2008 Sep;111(2):389-90.

doi: 10.1007/s10549-007-9777-3. Epub 2007 Oct 4.

Authors

Danila Coradini, Manuela Gariboldi, Maya Fedeli, Marco A Pierotti, Maria Grazia Daidone

PMID: 17914668
DOI: 10.1007/s10549-007-9777-3

No abstract available

PubMed Disclaimer

Similar articles

[Adjuvant tamoxifen in breast cancers with negative estrogen receptors. Complete review of the literature].
Namer M, Poterre M. Namer M, et al. Bull Cancer. 1992;79(3):297-9. Bull Cancer. 1992. PMID: 1392169 Review. French. No abstract available.
Different prognostic significance of CD24 and CD44 expression in breast cancer according to hormone receptor status.
Kim HJ, Kim MJ, Ahn SH, Son BH, Kim SB, Ahn JH, Noh WC, Gong G. Kim HJ, et al. Breast. 2011 Feb;20(1):78-85. doi: 10.1016/j.breast.2010.08.001. Breast. 2011. PMID: 20810282
Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy.
Honma N, Horii R, Iwase T, Saji S, Younes M, Takubo K, Matsuura M, Ito Y, Akiyama F, Sakamoto G. Honma N, et al. J Clin Oncol. 2008 Aug 1;26(22):3727-34. doi: 10.1200/JCO.2007.14.2968. J Clin Oncol. 2008. PMID: 18669459
A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA, Robertson KE, Ravel P, Bray SE, Bajard A, Purdie CA, Nguyen C, Hadad SM, Bieche I, Chabaud S, Bachelot T, Thompson AM, Cohen PA. Vendrell JA, et al. Breast Cancer Res. 2008;10(5):R88. doi: 10.1186/bcr2158. Epub 2008 Oct 17. Breast Cancer Res. 2008. PMID: 18928543 Free PMC article.
Understanding the BIG results: Insights from the BIG 1-98 trial analyses.
Wardley AM. Wardley AM. Adv Ther. 2008 Dec;25(12):1257-75. doi: 10.1007/s12325-008-0128-5. Adv Ther. 2008. PMID: 19096768 Review.

See all similar articles

Cited by

Breast cancer-initiating cells: insights into novel treatment strategies.
Santilli G, Binda M, Zaffaroni N, Daidone MG. Santilli G, et al. Cancers (Basel). 2011 Mar 16;3(1):1405-25. doi: 10.3390/cancers3011405. Cancers (Basel). 2011. PMID: 24212666 Free PMC article.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Springer
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal